- Home
- ATOS vs XBIT Comparison
ATOS vs XBIT Comparison
Compare ATOS & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- XBIT
- Stock Information
- Founded
- ATOS 2009
- XBIT 2005
- Country
- ATOS United States
- XBIT United States
- Employees
- ATOS N/A
- XBIT N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- XBIT Pharmaceuticals and Biotechnology
- Sector
- ATOS Health Care
- XBIT Health Care
- Exchange
- ATOS Nasdaq
- XBIT Nasdaq
- Market Cap
- ATOS 107.2M
- XBIT 86.3M
- IPO Year
- ATOS 2012
- XBIT 2015
- Fundamental
- Price
- ATOS $0.84
- XBIT $2.75
- Analyst Decision
- ATOS Strong Buy
- XBIT
- Analyst Count
- ATOS 3
- XBIT 0
- Target Price
- ATOS $6.17
- XBIT N/A
- AVG Volume (30 Days)
- ATOS 483.0K
- XBIT 52.7K
- Earning Date
- ATOS 11-11-2025
- XBIT 11-12-2025
- Dividend Yield
- ATOS N/A
- XBIT N/A
- EPS Growth
- ATOS N/A
- XBIT N/A
- EPS
- ATOS N/A
- XBIT N/A
- Revenue
- ATOS N/A
- XBIT N/A
- Revenue This Year
- ATOS N/A
- XBIT N/A
- Revenue Next Year
- ATOS N/A
- XBIT N/A
- P/E Ratio
- ATOS N/A
- XBIT N/A
- Revenue Growth
- ATOS N/A
- XBIT N/A
- 52 Week Low
- ATOS $0.55
- XBIT $2.50
- 52 Week High
- ATOS $1.66
- XBIT $8.32
- Technical
- Relative Strength Index (RSI)
- ATOS 60.84
- XBIT 36.07
- Support Level
- ATOS $0.81
- XBIT $2.72
- Resistance Level
- ATOS $0.80
- XBIT $3.61
- Average True Range (ATR)
- ATOS 0.03
- XBIT 0.18
- MACD
- ATOS 0.01
- XBIT -0.06
- Stochastic Oscillator
- ATOS 92.67
- XBIT 5.49
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.